Business Context and Reporting Period
This Form 8-K Current Report was filed by BioRestorative Therapies, Inc. on April 2, 2015, covering events occurring between April 2, 2015, and April 8, 2015. The filing primarily addresses changes to the Company's Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Joseph B. Swiader resigned as a director on April 2, 2015, citing other business commitments.
- Director Election: Charles S. Ryan, J.D., Ph.D., was elected as a director on April 6, 2015. He was appointed to the Audit Committee and the Nominating Committee.
- Compensatory Arrangement: Concurrent with his election, Dr. Ryan was granted an option to purchase 300,000 shares of common stock at an exercise price of $0.40 per share under the 2010 Equity Participation Plan.
- Vesting Schedule: The option vests in three equal tranches of 100,000 shares on the first, second, and third anniversaries of the grant date. The option is exercisable for ten years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document serves solely to disclose the personnel changes and the associated stock option grant.
Investor Verification Checklist
- Verify the independence status of the newly elected director, Dr. Charles S. Ryan, particularly regarding his appointment to the Audit Committee.
- Review the terms of the 2010 Equity Participation Plan to confirm the valuation and accounting treatment of the 300,000 share option grant.
- Confirm the current composition of the Board of Directors following the resignation of Mr. Swiader.
- Check for any subsequent filings regarding the press release issued on April 8, 2015, referenced as Exhibit 99.1.